Immunotherapy in myeloma Infosheet

This Horizons Infosheet provides information on immunotherapy, a type of treatment being investigated in myeloma. This Infosheet covers key topics about immunotherapy including:

  • What is immunotherapy and how does it work in myeloma?
  • Immunotherapy currently in use in myeloma (including immunomodulatory drugs, monoclonal antibodies and allogeneic (donor) stem cell transplantation)
  • How do antibodies and monoclonal antibodies work?
  • New types of immunotherapy in development (including antibody-drug conjugates, bispecific antibodies and CAR-T cell treatments)
  • What are the potential side effects of immunotherapy?
  • Availability of newer immunotherapies in the UK
  • How do I take part in a clinical trial of an immunotherapy?
  • Future directions in immunotherapy research

Key points you can read about in this Infosheet include:

  • Myeloma cells can escape the body’s immune system in a variety of ways. The aim of immunotherapies is to stimulate the immune system to work harder or smarter to kill myeloma cells
  • Some myeloma drugs already in use are immunotherapies, for example thalidomide and daratumumab
  • A number of new types of immunotherapy are being developed to treat myeloma. These include CAR-T cell treatments, antibody-drug conjugates and bispecific antibodies
  • You may be treated with one of the newer immunotherapies as part of a clinical trial
  • Clinical trials and other research are helping scientists to understand better how the immune system works, and ways to harness it to treat myeloma

Myeloma UK Immunotherapy Horizons Infosheet

PDF / 414KB Download
Close-up photograph of a hand holding a mobile phone.

Stay in touch

We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.